Skip to content
vaccines hero image
vaccines hero image

Vaccines

Vaccines contain antigenic substances capable of inducing immunity against an infective agent or toxin.

They are frequently administered prophylactically but are increasingly being researched and developed in a therapeutic context (eg cancer vaccines which are designed to equip a patient’s immune system to treat an existing cancer).

While the global market for vaccines is less than 3% of the total pharmaceuticals market, World Health Organization research suggests that over the next few years, the vaccine market will enjoy a growth rate of 10% to 15% per year versus the 5% to 7% seen in the overall market.

To take a share of this expanding market, companies must navigate a number of challenges. The assessment, licensing and control of vaccines (which are biological medicinal products) occurs in an environment of rapid innovation and complex quality concerns. Our deep experience of vaccines, combined with the fact that our team includes lawyers with degrees in relevant scientific areas (molecular biology, biochemistry, genetics etc), enables us to quickly grasp evolving issues and technical concepts and provide nuanced and tailored advice.

We are trusted by many of the world’s leading vaccine companies to help them navigate all stages of the vaccine lifecycle. Our clients include Merck, GlaxoSmithKline, Johnson & Johnson, Pfizer and Novartis.

News & insights

Windows reflecting the sky

Publications: 20 January 2022

Kickoff of the UPC: UPC Protocol on Provisional Application now in force

On 19 January 2022, the Unified Patent Court (UPC) came to life as an international organisation. Now, the preparatory phase for the official start of the UPC system can begin.

Read more
Computer circuit board reflecting green, blue and yellow light

News: 12 January 2022

Technology deals dominate the 2021 global M&A market

Allen & Overy’s latest M&A Insights report* shows that that the value of global M&A transactions surged to a record high of nearly USD5.8 trillion in 2021, an increase of 64% on 2020, and 48% higher…

Read more
Microscopic image of cell

Blog Post: 05 January 2022

COVID-19 – the distinction between vaccines and vaccination

Vaccines With thanks to a huge global scientific effort, we now have several COVID-19 vaccines that have met the standards of safety and efficacy set by regulators. 

Read more
Vials of medication during production

Publications: 15 December 2020

Healthcare accent is on smaller deals

Transactions in the U.S. healthcare space rebounded in autumn, although with a greater proportion of smaller deals than in recent years. 

Read more

Download our sector brochure

Life sciences A&O red molecules

An insight in to our Life Science and Healthcare sector 2022

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.